What makes India the 'pharmacy of the world'?

India earned this title due to its dominant position in global generic drug manufacturing and supply. The country supplies over 50% of global vaccine demand, 40% of generic drug demand in the US, and 25% of all medicines in the UK. This dominance stems from cost-effective manufacturing capabilities, skilled workforce, regulatory compliance with international standards, and supportive policy frameworks that encouraged generic drug development post-1970 Patents Act.

How does DPCO 2013 control drug prices in India?

DPCO 2013 empowers NPPA to fix ceiling prices for 384 essential medicines listed in the National List of Essential Medicines (NLEM). Prices are calculated as simple average of all brands with ≥1% market share. For non-scheduled drugs, NPPA monitors prices and restricts annual increases to 10% of Maximum Retail Price. The mechanism aims to balance affordability with reasonable returns to manufacturers while ensuring access to essential medicines.

What are the main challenges facing India's pharmaceutical R&D?

Indian pharmaceutical companies typically invest only 6-8% of revenue in R&D compared to 15-20% globally. Key challenges include focus on generic drugs rather than innovation, limited funding for long-term research, regulatory complexities for new drug approvals, high failure rates in drug development, and preference for low-risk reverse engineering over novel drug discovery. The industry's cost-focused business model has historically prioritized manufacturing efficiency over research investment.

How has the Patents Act 2005 impacted India's pharmaceutical industry?

The Patents Act 2005 introduced product patents for pharmaceuticals, ending the era of process patents that enabled easy reverse engineering. While initially feared to reduce generic drug availability, the industry successfully adapted by focusing on complex generics, biosimilars, and leveraging TRIPS flexibilities like Section 3(d) to prevent patent evergreening. The Act also encouraged genuine innovation while maintaining access to affordable medicines through provisions like compulsory licensing.

What is the role of NPPA in pharmaceutical pricing?

NPPA (National Pharmaceutical Pricing Authority) is the apex body for pharmaceutical pricing in India, established in 1997. It fixes/revises prices of scheduled formulations under DPCO, monitors prices of non-scheduled formulations, and ensures availability of medicines at reasonable prices. NPPA also recovers overcharged amounts from manufacturers, maintains a price monitoring and resource unit, and provides data support for policy formulation in pharmaceutical pricing.

How has COVID-19 impacted India's pharmaceutical sector?

COVID-19 highlighted both strengths and vulnerabilities of India's pharmaceutical sector. Positively, India became a crucial global supplier of COVID-19 vaccines and essential medicines through initiatives like Vaccine Maitri. However, the pandemic exposed heavy dependence on China for APIs (68% of imports), leading to supply chain disruptions. This prompted government initiatives like PLI scheme to boost domestic API manufacturing and reduce import dependence.

What government initiatives support the pharmaceutical sector?

Key government initiatives include the Production Linked Incentive (PLI) scheme with ₹15,000 crore outlay for critical APIs and medical devices, establishment of three bulk drug parks for world-class API manufacturing infrastructure, Pharmaceutical Research and Development Support Fund for innovation, and various export promotion measures. The Atmanirbhar Bharat initiative emphasizes self-reliance in pharmaceutical inputs, while schemes like Pharma Vision 2020 provide strategic direction for sector development.

← ALL TOPICS

Indian Economy

NEXT TOPIC →

Healthcare Expenditure

Pharmaceutical Industry

Indian Economy

Constitution VerifiedUPSC Verified

Version 1Updated 5 Mar 2026

Explore This Topic

Definition Detailed Explanation Key Judgments Economic Framework Policy Reforms UPSC Importance Prelims Strategy Mains Strategy Prelims MCQs Mains Questions MCQ Practice Predicted 2026 Revision Notes Current Affairs

The pharmaceutical industry in India is regulated under the Drugs and Cosmetics Act, 1940, and the Patents Act, 1970 (amended in 2005). The Drug Price Control Order (DPCO) 2013, issued under the Essential Commodities Act, 1955, empowers the National Pharmaceutical Pricing Authority (NPPA) to fix/revise the prices of scheduled formulations and monitor prices of non-scheduled formulations. The indus…

Quick Summary

India's pharmaceutical industry is the world's largest supplier of generic drugs, earning the title 'pharmacy of the world' by supplying 50% of global vaccine demand and 40% of US generic drug requirements.

The domestic market is valued at $50 billion with exports of$ 25.4 billion in FY 2022-23. The industry operates under a complex regulatory framework including CDSCO for drug approvals, NPPA for price control under DPCO 2013, and Patents Act 2005 for intellectual property.

Key policy milestones include the Patents Act 1970 (enabling generic drug development through process patents), liberalization in 1991, and TRIPS compliance through Patents Act 2005. The sector employs 4.

7 million people and contributes significantly to India's export earnings. Major companies include Sun Pharma, Dr. Reddy's, Cipla, and Aurobindo Pharma. Challenges include limited R&D investment (6-8% vs global 15-20%), quality concerns, and dependence on Chinese APIs (68% of imports).

Government support includes PLI scheme (₹15,000 crores), bulk drug parks, and Atmanirbhar Bharat initiatives. COVID-19 highlighted both the sector's global importance through vaccine diplomacy and vulnerabilities in API supply chains.

The industry's future growth depends on addressing R&D gaps, quality improvements, and reducing import dependence while maintaining cost competitiveness in global markets.

Vyyuha

Your 6-Month Blueprint, Updated Nightly

AI analyses your progress every night. Wake up to a smarter plan. Every. Single.…

India = 'Pharmacy of the world': 50% global vaccines, 40% US generics

Market size:

50B domestic,

25.4B exports (FY23)

Key regulators: CDSCO (approvals), NPPA (pricing)

DPCO 2013: 384 essential medicines price control

Patents Act: 1970 (process) → 2005 (product, TRIPS)

Major challenge: 68% API imports from China

PLI scheme: ₹15,000 cr for 53 critical APIs

Top companies: Sun Pharma, Dr. Reddy's, Cipla

Employment: 4.7 million direct + indirect

Generic drugs: 70% domestic market share

Vyyuha Quick Recall - PHARMA: Production (50% global vaccines, 40% US generics), Hubs (Sun Pharma, Dr. Reddy's, Cipla leading), APIs (68% from China, PLI ₹15,000cr), Regulation (CDSCO approvals, NPPA pricing), Market ( $50B domestic,$ 25.4B exports), Acts (1970 process → 2005 product patents). Remember: 384 medicines under DPCO 2013, 4.7 million employment, 70% generic market share, 2000+ facilities globally approved.

Pharmaceutical Industry

Quick Summary

Related Topics